Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Improving Global Access to Genomic Profiling in Rare Pediatric Cancers.
Farouk Sait S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Comparison of Comprehensive Genomic Profiling Testing "Ion Torrent Genexus Sequencer" With FoundationOne.
Fujiyoshi K et al.
Anticancer Research, 2025
Effects of F53 hotspot mutations on the molecular dynamics of MEK1 protein and the binding of its FDA-approved inhibitors.
Vural BE et al.
International Journal of Biological Macromolecules, 2025
Clinical, Morphological and Molecular Features of Spitz tumors.
Donati M et al.
Ceskoslovenska Patologie, 2024
Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic Tumors With Activating Mutations in MAP2K1.
Fumero-Velázquez M et al.
The American Journal of Surgical Pathology, 2023
TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y et al.
Journal of Translational Medicine, 2023
Evolutionary history of MEK1 illuminates the nature of deleterious mutations.
Andrianova EP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.
Mizuno S et al.
Molecular Cancer Therapeutics, 2023
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.
Farnsworth DA et al.
Npj Precision Oncology, 2022
Rosai-Dorfman Disease between Proliferation and Neoplasia.
Elbaz Younes I et al.
Cancers, 2022
A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile.
Salmeron-Villalobos J et al.
Blood Advances, 2022
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
Frauenfeld L et al.
Blood Advances, 2022
Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.
Zhang W et al.
Bmc Cancer, 2020
Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease.
Baraban E et al.
British Journal of Haematology, 2019
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets.
Carlo MI et al.
Jco Precision Oncology, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.
Garces S et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2017